Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
cells with sufficient energy are energetic
Slow escalation, missed injections, and inconsistent diet all delay progress
With a team of experienced medical professionals, state-of-the-art technology, and a commitment to excellence, we provide top-notch care no matter where you are in the United States
Weight loss can be difficult
Figure 1: Percentage risk reduction with GLP-1 therapy across indications based on selected real-world studies: Sources: 1
